Core Insights - Wall Street analysts expect Agilent Technologies to report quarterly earnings of $1.37 per share, reflecting a year-over-year increase of 4.6% and revenues of $1.8 billion, up 7.2% from the previous year [1] Revenue Estimates by End Markets - Revenue from Chemical and Advanced Materials is projected to reach $413.46 million, indicating a year-over-year increase of 9.1% [4] - Revenue from Environmental and Forensics is expected to be $173.75 million, suggesting a 1% increase year-over-year [4] - Revenue from Diagnostics and Clinical is forecasted at $254.20 million, reflecting a 5.9% increase from the prior year [5] - Revenue from Academia and Government is estimated to be $144.50 million, indicating a 5.5% year-over-year increase [5] - Revenue from Pharmaceuticals is projected at $633.34 million, suggesting an 8.3% increase year-over-year [6] - Revenue from Food is expected to reach $166.52 million, indicating a slight decrease of 0.9% from the previous year [6] Net Revenue Estimates - Net Revenue from the Americas is expected to be $704.33 million, reflecting a year-over-year increase of 5.3% [6] - Net Revenue from Asia Pacific is projected at $604.90 million, indicating a 10.2% increase year-over-year [7] - Net Revenue from Europe is estimated to be $486.16 million, suggesting a 5% increase from the prior year [7] Stock Performance - Agilent's shares have decreased by 8.9% over the past month, compared to a 0.8% decline in the Zacks S&P 500 composite [7] - The company holds a Zacks Rank of 3 (Hold), indicating expectations to mirror overall market performance in the near future [7]

Core Viewpoint - Analysts project that Viper Energy Partners (VNOM) will report quarterly earnings of $0.27 per share, reflecting a year-over-year decline of 35.7%, while revenues are expected to reach $426.49 million, an increase of 86.5% from the same quarter last year [1]. Earnings Estimates - Over the last 30 days, the consensus EPS estimate has been revised downward by 5.9%, indicating a collective reassessment by analysts of their initial forecasts [2]. - Revisions to earnings estimates are crucial indicators for predicting investor actions regarding the stock, with empirical research showing a strong correlation between earnings estimate trends and short-term stock price performance [3]. Revenue and Income Projections - Analysts estimate 'Natural Gas Income' will reach $23.50 million, a year-over-year increase of 288.5% [5]. - 'Natural Gas Liquids Income' is projected at $47.99 million, reflecting a change of 79.3% from the previous year [5]. - 'Oil income' is expected to be $359.92 million, indicating an increase of 87.4% year-over-year [5]. Production Metrics - 'Lease bonus income' is estimated to be $10.06 million, a change of 175.2% from the year-ago quarter [6]. - The average daily combined volumes are projected at 126,597 barrels of oil equivalent per day, compared to 56,109 barrels of oil equivalent per day from the previous year [6]. - 'Total Production' is forecasted to reach 11,671 thousand barrels of oil equivalent, up from 5,162 thousand barrels of oil equivalent in the same quarter last year [7]. Sales Price Estimates - The 'Average sales prices - Natural gas liquids' is expected to be $17.26, down from $22.15 in the same quarter last year [7]. - The 'Average sales prices - Oil, hedged' is projected at $58.59, compared to $69.00 reported in the same quarter last year [9]. - 'Average sales prices - Crude Oil' is expected to be $58.46, down from $69.91 in the same quarter last year [9]. Stock Performance - Over the past month, Viper Energy shares have returned +14.8%, contrasting with the Zacks S&P 500 composite's -0.8% change [10]. - Based on its Zacks Rank 4 (Sell), VNOM is expected to underperform the overall market in the upcoming period [10].

Core Insights - Newmont Corporation (NEM) reported fourth-quarter 2025 earnings of $1.19 per share, a decrease from $1.24 in the same quarter last year, but adjusted earnings rose to $2.52 per share from $1.40, exceeding the Zacks Consensus Estimate of $2.03 [1][8] Financial Performance - Revenues for the fourth quarter reached $6,818 million, a 20.6% increase from $5,652 million in the prior-year quarter, surpassing the Zacks Consensus Estimate of $6,056 million, driven by higher realized gold prices [2][8] - The company's cash and cash equivalents stood at $7,647 million, up 111.3% year over year, while long-term debt decreased by 32.3% to $5,115 million [5][8] Operational Highlights - Attributable gold production for the fourth quarter was 1.45 million ounces, a 2% increase from the previous quarter but down 23.7% year over year, exceeding the estimate of 1.42 million ounces [3][8] - Average realized gold prices increased by 59.5% year over year to $4,216 per ounce, surpassing the estimate of $3,560 per ounce [3][8] Cost Analysis - Costs applicable to sales (CAS) for gold were $1,166 per ounce, a 6.4% increase year over year, but below the estimate of $1,175 per ounce [4] - All-in-sustaining costs (AISC) for gold rose by 10.7% year over year to $1,620 per ounce, higher than the estimate of $1,531 per ounce [4] Future Outlook - Newmont anticipates gold production for 2026 to be approximately 5.26 million ounces, with projected total CAS for gold at $1,055 per ounce and AISC at $1,680 per ounce [6] - General and Administrative expenses for 2026 are expected to be around $375 million, with reclamation and remediation accretion projected at $385 million and exploration expenses at $525 million [6] Stock Performance - Newmont's shares have increased by 176.6% over the past year, outperforming the industry average rise of 144.4% [7][8]

Core Insights - Fidelity National Information Services, Inc. (FIS) is scheduled to report its fourth-quarter 2025 results on February 24, 2026, with earnings estimated at $1.69 per share and revenues at $2.74 billion [1][4] Financial Performance Estimates - The fourth-quarter earnings estimate has seen two downward revisions in the past 30 days, indicating a 20.7% year-over-year increase in earnings and a 5.4% increase in revenues [2][4] - For the full year 2025, the revenue estimate is $10.59 billion, reflecting a 4.6% year-over-year rise, while the EPS estimate is $5.77, indicating a growth of approximately 10.5% year-over-year [4] Earnings Prediction Model - The current model does not predict an earnings beat for FIS, with an Earnings ESP of -0.37% and a Zacks Rank of 3 (Hold) [5] Revenue Breakdown - Q4 revenues are expected to show growth in Banking Solutions and Capital Market Solutions, with increases of 6.4% and 6.6% year-over-year, respectively [8][9] - Total recurring revenues are projected to increase by 7.9% in the upcoming quarter, with North America and All Other revenues expected to grow by 6.5% and 0.5% year-over-year, respectively [9] EBITDA Projections - The adjusted EBITDA for 2025 is projected to be between $4.33 billion and $4.345 billion, with an anticipated margin of around 40.9% [8][11] - The adjusted EBITDA for Capital Market Solutions is expected to grow by 6% year-over-year, while Banking Solutions is projected to see a 10.9% increase [10]

Core Viewpoint - Entrada Therapeutics, Inc. (TRDA) is anticipated to report a significant year-over-year decline in earnings and revenues for the quarter ended December 2025, which could impact its stock price depending on the actual results compared to estimates [1][3]. Earnings Expectations - The consensus estimate indicates a quarterly loss of $1.32 per share, reflecting a drastic year-over-year change of -4500% [3]. - Expected revenues are projected at $1.29 million, down 96.6% from the same quarter last year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised down by 1.52%, indicating a reassessment by analysts regarding the company's earnings prospects [4]. - The Most Accurate Estimate for Entrada Therapeutics is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -59.09%, suggesting a bearish outlook from analysts [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the deviation of actual earnings from consensus estimates, but it is more reliable for positive readings [9][10]. - The current Zacks Rank for Entrada Therapeutics is 3, which complicates the prediction of an earnings beat [12]. Historical Performance - In the last reported quarter, Entrada Therapeutics was expected to post a loss of $1.04 per share but actually reported a loss of -$1.06, resulting in a surprise of -1.92% [13]. - Over the past four quarters, the company has beaten consensus EPS estimates twice [14]. Conclusion - Overall, Entrada Therapeutics does not appear to be a strong candidate for an earnings beat, and investors should consider other factors before making investment decisions [17].

Core Viewpoint - The market anticipates TeraWulf Inc. (WULF) will report a year-over-year decline in earnings despite higher revenues in its upcoming earnings report for the quarter ended December 2025 [1] Earnings Expectations - The consensus EPS estimate for TeraWulf is a loss of $0.13 per share, reflecting a year-over-year decline of 62.5% [3] - Expected revenues are projected at $43.55 million, which is an increase of 24.5% compared to the same quarter last year [3] Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised down by 0.95%, indicating a reassessment by analysts regarding the company's earnings prospects [4] - The Most Accurate Estimate for TeraWulf is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -41.79%, suggesting a bearish outlook from analysts [12] Earnings Surprise Prediction - A positive Earnings ESP is generally a strong indicator of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [10] - TeraWulf currently holds a Zacks Rank of 2, but the negative Earnings ESP complicates predictions of an earnings beat [12] Historical Performance - In the last reported quarter, TeraWulf was expected to post a loss of $0.04 per share but actually reported a loss of $0.07, resulting in a surprise of -75.00% [13] - The company has not exceeded consensus EPS estimates in any of the last four quarters [14]

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Curaleaf Holdings, Inc. due to lower revenues, with a focus on how actual results will compare to estimates [1][2]. Earnings Expectations - Curaleaf is expected to report a quarterly loss of $0.08 per share, reflecting a significant year-over-year change of -500% [3]. - Revenues are projected to be $327.84 million, which is a decrease of 1% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 2.22% over the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Curaleaf is lower than the Zacks Consensus Estimate, leading to an Earnings ESP of -3.23% [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from consensus estimates, with a strong predictive power for positive readings [7][8]. - Curaleaf's current Zacks Rank is 4, which complicates the prediction of an earnings beat [11]. Historical Performance - In the last reported quarter, Curaleaf was expected to post a loss of $0.07 per share but actually reported a loss of -$0.06, resulting in a surprise of +14.29% [12]. - Over the past four quarters, Curaleaf has beaten consensus EPS estimates three times [13]. Conclusion - Curaleaf Holdings, Inc. does not appear to be a strong candidate for an earnings beat, and investors should consider other factors when making decisions regarding the stock ahead of the earnings release [16].

Core Viewpoint - Fidelity National Information Services (FIS) is expected to report quarterly earnings of $1.69 per share, reflecting a 20.7% increase year-over-year, with revenues projected at $2.74 billion, a 5.4% increase compared to the previous year [1]. Earnings Estimates - The consensus EPS estimate has been revised down by 0.2% in the last 30 days, indicating a reassessment by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock performance [3]. Revenue Projections - Analysts estimate 'Revenue- Banking Solutions' at $1.83 billion, a year-over-year increase of 6.4% [5]. - 'Revenue- Capital Market Solutions' is expected to reach $874.74 million, reflecting a 6.6% year-over-year increase [5]. - 'Revenue- Corporate and Other' is projected at $44.78 million, indicating a significant decline of 26.6% from the previous year [5]. - The consensus estimate for 'Revenue- Total Recurring' stands at $2.18 billion, showing a year-over-year increase of 7.9% [6]. EBITDA Estimates - Analysts project 'Adjusted EBITDA- Banking Solutions' to be $810.47 million, up from $731.00 million reported in the same quarter last year [6]. - 'Adjusted EBITDA- Capital Market Solutions' is forecasted to reach $479.95 million, compared to $453.00 million in the same quarter of the previous year [7]. Stock Performance - Shares of Fidelity National have decreased by 19.8% over the past month, contrasting with a 0.8% decline in the Zacks S&P 500 composite [7].

Core Insights - Nutrien Ltd. reported a significant profit increase to $580 million or $1.18 per share for Q4 2025, up from $118 million or 23 cents in the same quarter last year [1] - Adjusted earnings per share, excluding one-time items, were 83 cents, an increase from 31 cents year-over-year, although it fell short of the Zacks Consensus Estimate of 87 cents [1] - Sales rose approximately 5% year-over-year to $5,340 million, surpassing the Zacks Consensus Estimate of $5,207.3 million [1] Segment Performance - The Nutrien Ag Solutions (Retail) segment experienced a 1% decline in sales year-over-year, totaling $3,144 million, attributed to lower sales volumes and reduced demand for phosphate, yet it exceeded the estimate of $2,883.3 million [2] - The Potash division saw a 37% year-over-year increase in sales, reaching $736 million, although it missed the estimate of $857.9 million due to lower sales volumes [3] - The Nitrogen segment reported sales of $1,093 million, an 11% increase year-over-year, beating the estimate of $657.6 million, despite a decline in sales volumes due to facility shutdowns [4] - The Phosphate segment generated sales of $483 million, up around 17% year-over-year, exceeding the estimate of $288.1 million [4] Financial Overview - At the end of the quarter, Nutrien had cash and cash equivalents of $701 million, down approximately 18% year-over-year, while long-term debt increased by 5.3% to $9,350 million [5] - Cash provided from operating activities was reported at $2,977 million for the quarter [5] Future Outlook - The company projects retail adjusted EBITDA for 2026 to be between $1.75 billion and $1.95 billion, indicating high-single digit growth in proprietary products gross margins and mid-single digit increases in North American crop nutrient sales volumes [6] - Expected potash sales volumes are projected to be between 14.1 million and 14.8 million tons, while nitrogen sales volumes are forecasted at 9.2 million to 9.7 million tons [7] - Capital expenditures are anticipated to be between $2 billion and $2.1 billion, including $400 million for growth investments [8]

Core Viewpoint - HudBay Minerals (HBM) is expected to report a significant year-over-year improvement in earnings for Q4 2025, with an estimated EPS of 40 cents, reflecting a 122.2% increase from 18 cents in Q4 2024 [1][2]. Financial Estimates - The Zacks Consensus Estimate for Q4 2025 EPS is 0.40, with a range of estimates from 0.32 to 0.46 [2]. - Year-over-year growth estimates for EPS are 122.22% for Q4 2025, 62.50% for Q1 2026, 75.00% for the current year, and 86.97% for the next year [2]. Earnings Surprise History - HudBay Minerals has beaten Zacks Consensus Estimates in two of the last four quarters, with an average surprise of 40.68% [3][4]. Factors Influencing Q4 Performance - The anticipated recovery in Q4 performance is attributed to deferred copper shipments and strong production in October, alongside effective cost controls and high gold prices [7][10]. - A deferral of 20,000-tonne copper concentrate shipment from Peru is expected to positively impact sales [8]. - Despite challenges in Q3 due to wildfires and social unrest, the operational environment is characterized as manageable, with strong production in October [9]. Production and Cost Management - Gold production is projected to slightly fall below guidance due to a power outage, but operational efficiency has improved, with cash costs declining to $379 per ounce [10][12]. - Cost-control initiatives have led to a tightening of cash cost guidance, which is expected to support earnings [12]. Market Performance - HudBay Minerals shares have increased by 225.5% over the past year, outperforming the industry growth of 48.9% and the S&P 500's return of 13.6% [15]. - The company has also outperformed peers like SSR Mining and Wheaton Precious Metals, which saw share increases of 146.3% and 105%, respectively [17].